July 13, 2016
Amgen and Daiichi Sankyo Company, Limited have announced the execution of an exclusive agreement for commercializing nine biosimilars in Japan. This deal comprises several biosimilars in late-stage development, including biosimilars of adalimumab, trastuzumab, and bevacizumab.
According to the terms of the agreement, Amgen will remain responsible for developing and manufacturing the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan. However, Amgen will have a limited right to co-promote the products.
Scott Foraker, vice president and general manager of Biosimilars at Amgen, said: “Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide”.
Outside of Japan, Amgen will retain all additional distribution and commercialization rights for the biosimilar programs. Specific financial terms of the agreement were not revealed.Amgen and Daiichi Sankyo Announce Agreement for Commercializing Biosimilars in Japan last edit: 2016-07-22T17:33:24+00:00 da